Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study

Final survival results from TITAN, after unblinding and placebo-to-apalutamide crossover, found apalutamide plus androgen deprivation therapy improved overall survival (HR 0.52; 95% CI 0.42 to 0.64; P <0.0001), delayed second progression-free survival and castration resistance.

Journal of Clinical Oncology